https://www.selleckchem.com/pr....oducts/acalabrutinib
Insufficient drug accumulation and chemoresistance remain two major challenges in cancer chemotherapy. Herein, we designed a furin-responsive aggregated nanoplatform loaded with doxorubicin (DOX) and hydroxychloroquine (HCQ) (AuNPs-DH-RC) to combine chemotherapy, autophagy inhibition and macrophage polarization. AuNPs-DH-RC could passively target breast tumor via enhanced permeability and retention (EPR) effect after systemic administration and further aggregate together triggered by furin overexpressed in brea
Like
Comment
Share
